Image: BakiBG/Getty
Delaware-based BloodGPT, which develops tools to help diagnostic laboratories and clinics streamline their test analyses with its AI-powered platform, has launched biomarker-based nutrition planning for patients.
WHY IT MATTERS
The platform provides a data-driven alternative to risky supplement guesswork, the company says, offering patients an evidence-based path from lab results to healthier behaviors by generating personalized plans tied to their own bloodwork.
By analyzing biomarker readings and weighing them against clinical ranges, BloodGPT's platform can generate personalized nutrition plans from a curated database through a structured decision framework.
More than 10% of global deaths are associated with poor diets, the company notes.
"It’s high time we changed our approach to nutrition guidance," said Nikita Udovichenko, BloodGPT cofounder, biochemist and endocrinology expert, in a statement. "In healthcare, there’s no such thing as neutral – if you ignore a problem, it gets worse over time."
By transforming raw results into visually clear, understandable explanations with integrated nutrition advice, BloodGPT can help patients interested in their test results take action.
The company said that based on research, 71% of patients who get clear explanations of abnormal lab results will follow up with their doctors, compared with only 49% who see the raw data alone.
If the platform can increase patient follow-up, it could help providers better tackle diet-related diseases, which cause more than one million deaths each year.
Those results could support healthcare providers with their costs. With the average clinic running 20,000 tests monthly, the feature could save 600 physician hours with a nearly 800% ROI, the company said.
Of note, BloodGPT is HIPAA-compliant and said no information is shared with third-party vendors, and patient data is kept on a dedicated server.
THE LARGER TREND
Biomarker testing is fast becoming much more common and more integrated into several areas of healthcare – enabling more patients to access precision medicine treatments.
"Research has shown that it drastically improves outcomes for patients suffering from various illnesses and conditions, including different forms of cancer, arthritis, Parkinson's and more," said New York state Sen. Roxanne Persaud when the state passed a law in 2023 that directed all state-regulated health plans, including Medicaid, to cover comprehensive biomarker testing.
This past August, new research published in the Journal of Alzheimer's Disease showed how digital assessments could uncover the earliest signs of cognitive impairment when two researchers demonstrated how subtle response-time biomarkers could detect Alzheimer's and dementia risk far earlier than traditional methods.
ON THE RECORD
"With BloodGPT, patients see how their choices move the needle on real biomarkers, and professionals can choose to use these insights to help deliver more precise, evidence-based care," said BloodGPT's Udovichenko in a statement.
Andrea Fox is senior editor of Healthcare IT News.
Email: afox@himss.org
Healthcare IT News is a HIMSS Media publication.
